LYRA · As filed with the SEC
Lyra Therapeutics cash flow statement, by fiscal year
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||
| Net loss | (28,919,000) | (93,435,000) | (62,680,000) | (55,278,000) | (43,513,000) | (22,127,000) | (16,306,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Stock-based compensation | 2,335,000 | 6,716,000 | 5,887,000 | 5,447,000 | 2,770,000 | 1,813,000 | 244,000 |
| Depreciation expense | 459,000 | 471,000 | 278,000 | 1,067,000 | 1,001,000 | 95,000 | 27,000 |
| Reserve for uncollectible accounts | — | — | — | — | — | — | 167,000 |
| Gain on disposal of assets | — | — | — | — | — | (45,000) | — |
| Impairment of property and equipment | — | 1,883,000 | 1,592,000 | 1,316,000 | — | — | — |
| Write-off of deferred financing costs | — | 140,000 | — | — | — | — | — |
| Impairment of right-of-use assets | — | 22,836,000 | — | — | — | — | — |
| Gain on sale of property and equipment | (8,000) | — | — | — | — | — | — |
| Net amortization of discount on short-term investments | — | (2,276,000) | (3,496,000) | (492,000) | — | — | — |
| Changes in operating assets and liabilities | |||||||
| Prepaid expenses and other current assets | 2,069,000 | (380,000) | 867,000 | (764,000) | (847,000) | (1,013,000) | 561,000 |
| Operating lease right-of-use assets | 3,132,000 | 1,353,000 | (5,137,000) | (868,000) | 946,000 | 894,000 | 864,000 |
| Other assets | — | 1,111,000 | 210,000 | (574,000) | (500,000) | (118,000) | — |
| Accounts payable | (516,000) | (1,887,000) | 450,000 | (2,411,000) | 2,350,000 | 345,000 | (205,000) |
| Accrued expenses and other current liabilities | — | — | 1,491,000 | 4,772,000 | 1,244,000 | (87,000) | 1,734,000 |
| Operating lease liabilities | — | — | — | — | — | (900,000) | (840,000) |
| Accrued expenses and other current liabilities | (1,811,000) | (5,975,000) | — | — | — | — | — |
| Restructuring liability | — | 4,347,000 | — | — | — | — | — |
| Restructuring liability | (1,081,000) | — | — | — | — | — | — |
| Operating lease liabilities | (4,121,000) | (3,381,000) | (1,208,000) | 763,000 | (986,000) | — | — |
| Deferred revenue | (398,000) | (1,534,000) | (1,558,000) | 3,637,000 | 11,715,000 | — | — |
| Net cash used in operating activities | (28,859,000) | (70,011,000) | (63,304,000) | (43,385,000) | (25,820,000) | (21,143,000) | (13,754,000) |
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | (116,000) | (2,338,000) | (1,047,000) | (164,000) | (3,385,000) | (1,775,000) | (211,000) |
| Proceeds from maturities of investments | — | — | 110,886,000 | — | — | — | — |
| Proceeds from the sale of property and equipment | 18,000 | — | — | — | — | — | — |
| Purchases of short-term investments | — | (47,949,000) | (122,423,000) | (64,842,000) | — | — | — |
| Maturity of short-term investments | — | 130,592,000 | — | — | — | — | — |
| Net cash (used in) provided by investing activities | (98,000) | 80,305,000 | (12,584,000) | (65,006,000) | (3,385,000) | (1,775,000) | (211,000) |
| Cash flows from financing activities: | |||||||
| Series C Preferred Stock | — | — | — | — | — | 30,392,000 | — |
| Series C Preferred Stock | — | — | — | — | — | (206,000) | — |
| Proceeds from initial public offering, net of underwriting discount | — | — | — | — | — | 59,892,000 | — |
| Payment of initial public offering costs | — | — | — | — | — | (2,383,000) | (226,000) |
| Proceeds from sale of common stock and pre-funded warrants | — | — | — | 100,495,000 | — | — | — |
| Proceeds from sale of common stock, warrants and pre-funded warrants | — | 8,818,000 | 69,242,000 | — | — | — | — |
| Proceeds from sale of common stock, warrants and pre-funded warrants | 4,999,000 | — | — | — | — | — | — |
| Payment of deferred offering costs | (726,000) | (290,000) | (3,654,000) | (4,246,000) | (245,000) | — | — |
| Proceeds from exercise of stock options | — | 3,000 | 103,000 | 8,000 | 604,000 | 8,000 | 111,000 |
| Net cash provided by financing activities | 4,273,000 | 8,531,000 | 65,691,000 | 96,257,000 | 359,000 | 87,703,000 | (115,000) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (24,684,000) | 18,825,000 | (10,197,000) | (12,134,000) | (28,846,000) | 64,785,000 | (14,080,000) |
| Cash, cash equivalents and restricted cash, beginning of period | 42,570,000 | 23,745,000 | 33,942,000 | 46,076,000 | 74,922,000 | 10,137,000 | 24,217,000 |
| Cash, cash equivalents and restricted cash, end of period | 17,886,000 | 42,570,000 | 23,745,000 | 33,942,000 | 46,076,000 | 74,922,000 | 10,137,000 |
| Supplemental disclosure of non-cash financing and investing activities: | |||||||
| Property and equipment purchases included in accounts payable and accrued expenses | — | — | 623,000 | — | 41,000 | 205,000 | 2,000 |
| Conversion of redeemable convertible preferred stock | — | — | — | — | — | 160,227,000 | — |
| Series C Preferred Stock | — | — | — | — | — | 740,000 | — |
| Accretion of redeemable convertible preferred stock to redemption value | — | — | — | — | — | 115,000 | 313,000 |
| Other Assets Included in Accounts Payable and Accrued Expenses | — | — | — | 1,960,000 | — | — | — |
| Prepaid expenses for right-of-use asset included in operating lease liabilities | — | — | 2,786,000 | — | — | — | — |
| Modification of lease agreement | — | — | 4,931,000 | 1,928,000 | — | — | — |
| Deferred offering costs included in accounts payable and accrued expense | — | — | — | — | 2,000 | — | 870,000 |
| Right-of-use asset in exchange for lease liability | — | — | 18,156,000 | — | — | — | — |
| Other assets included in accounts payable and other current liabilities | — | 13,667,000 | — | — | — | — | — |
| Right of Use Asset in Exchange for Lease Liability | — | — | — | — | — | 13,000 | 4,046,000 |
| Other assets included in accounts payable | — | — | — | — | 15,000 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.